4-苯基噻唑-2-羧酸 | 59020-44-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-苯基噻唑-2-羧酸
• 中文别名: 4-苯基-1,3-噻唑-2-甲酸
• 英文名称: 4-phenylthiazole-2-carboxylic acid
• 英文别名: 4-phenyl-1,3-thiazole-2-carboxylic acid
• CAS: 59020-44-9
• 化学式: C₁₀H₇NO₂S
• mdl: MFCD00990415
• 分子量: 205.237
• InChiKey: ORSGNNVYFOPYKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2934100090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Phenyl-1,3-thiazole-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Phenyl-1,3-thiazole-2-carboxylic acid
CAS number: 59020-44-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, under −20◦C.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H7NO2S
Molecular weight: 205.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-苯基噻唑-2-羧酸 在 草酰氯 作用下， 以 二氯甲烷 为溶剂， 生成 4-Phenylthiazole-2-carbonylchloride
  参考文献：
  名称：

  新型抗菌剂的制备。用杂环取代中心芳环。

  摘要：

  发现新型抗菌剂是一项重大挑战。最近，我们报道了我们发现的新型抗菌剂，其中我们已利用并行化学方法快速优化了药效。这些先进的铅对人血清白蛋白（HSA）具有很高的亲和力。为了降低对HSA的亲和力，我们制备了一系列杂环类似物，它们保留了抗菌活性，并降低了对HSA的亲和力。

  DOI：

  10.1016/j.bmcl.2006.12.055
• 作为产物：
  描述：

  4-苯基-1,3-噻唑-2-甲醛 在 sodium hydroxide 、 silver nitrate 作用下， 生成 4-苯基噻唑-2-羧酸
  参考文献：
  名称：

  Canas Rodriguez; Lopez Aparicio, Anales de la Real Sociedad Espanola de Fisica y Quimica, 1954, vol. 50, p. 609,614

  摘要：

  DOI：

文献信息

• Inhibitors of histone deacetylase
  申请人：——

  公开号：US20020177594A1

  公开（公告）日：2002-11-28

  Compounds having the formula 1 or therapeutically acceptable salts thereof, are histone deacetylase (HDAC) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are disclosed.

  具有以下化学式的化合物或其治疗上可接受的盐是组蛋白去乙酰化酶（HDAC）抑制剂。本文揭示了该化合物的制备、含有该化合物的组合物以及使用该化合物治疗疾病的方法。
• Synthesis of α‐Ketoamide‐Based Stereoselective Calpain‐1 Inhibitors as Neuroprotective Agents
  作者：Ammar Jastaniah、Irina N. Gaisina、Rachel C. Knopp、Gregory R. J. Thatcher

  DOI：10.1002/cmdc.202000385

  日期：2020.12.3

  potentially including ABT‐957 was optimized to yield diastereomerically pure compounds that are potent and selective for calpain‐1 over papain and cathepsins B and K. As the final oxidation step, with its optimized synthesis protocol, does not alter the configuration of the substrate, the synthesis of the diastereomeric pair (R)‐1‐benzyl‐N‐((S)‐4‐((4‐fluorobenzyl)amino)‐3,4‐dioxo‐1‐phenylbutan‐2‐yl)‐5‐oxopy

  钙蛋白酶抑制剂已被提议作为神经退行性疾病的候选药物，ABT-957 已进入阿尔茨海默病和轻度认知障碍的临床试验。ABT-957 的结构最近才被公开，由于 CNS 浓度不足以获得药效学效果，试验被终止。对可能包括 ABT-957 的 α-酮酰胺类肽模拟抑制剂系列的多步合成进行了优化，以产生非对映异构纯的化合物，这些化合物对 calpain-1 比木瓜蛋白酶和组织蛋白酶 B 和 K 更有效且具有选择性。作为最后的氧化步骤，其优化合成方案，不改变底物的构型，非对映体对 ( R )-1-苄基-N -(( S）-4 - （（4-氟苄基）氨基）-3,4-二氧代-1-苯基丁-2-基）-5-氧代吡咯烷-2-甲酰胺（图1c）和（- [R）-1-苄基- ñ - (( R )-4-((4-fluorobenzyl)amino)-3,4-dioxo-1-phenylbutan-2-yl)-5-oxopyrrolidine-2-carboxamide
• Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist
  作者：Lijun Hu、Qiang Ren、Liming Deng、Zongtao Zhou、Zongyu Cai、Bin Wang、Zheng Li

  DOI：10.1016/j.ejmech.2020.113106

  日期：2021.2

  Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent

  法尼醇X受体（FXR）是胆汁酸激活的核受体，调节胆汁酸和脂质的代谢，并维持内部环境的稳定性。FXR被认为是肝脏疾病（如药物性肝损伤，脂肪肝和胆汁淤积症）的治疗目标。先前报道的FXR部分激动剂6就其高强度和低分子大小而言是一种合适的先导化合物，而化合物6的对接研究则显示了一个较大的未占据的疏水口袋，这可能为结构活性关系提供了更多可能性（SAR ）学习。在这项研究中，我们基于铅化合物6进行了全面的SAR和分子建模研究。所有这些努力导致鉴定出一系列新的FXR部分激动剂。在该系列中，化合物41表现出最佳的活性，并且与FXR的结合口袋有很强的相互作用。此外，化合物41通过调节FXR相关基因的表达并提高抗氧化能力，保护小鼠免受对乙酰氨基酚诱导的肝毒性。总之，这些结果表明化合物41是一种有前途的FXR部分激动剂，适合进一步研究。
• Cyclic derivatives as modulators of chemokine receptor activity
  申请人：Carter H. Percy

  公开号：US20050054627A1

  公开（公告）日：2005-03-10

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

  当前申请描述了MCP-1的调节剂，其化学公式为(I):或其药用可接受的盐形式，用于治疗类风湿性关节炎、多发性硬化症、动脉粥样硬化和哮喘。
• [EN] THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE THIAZOLE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SCHERING CORP

  公开号：WO2009058728A1

  公开（公告）日：2009-05-07

  The present invention relates to novel Thiazole Derivatives, compositions comprising the Thiazole Derivatives, and methods for using the Thiazole Derivatives for treating or preventing a proliferative disorder, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral infection, a fungal infection, or a disorder related to the activity of a protein kinase.

  本发明涉及新型噻唑衍生物，包含该噻唑衍生物的组合物，以及使用该噻唑衍生物治疗或预防增生性疾病、抗增生性疾病、炎症、关节炎、中枢神经系统疾病、心血管疾病、脱发、神经疾病、缺血性损伤、病毒感染、真菌感染或与蛋白激酶活性相关的疾病的方法。